Takeda Oncology | Leading Cancer Treatment Innovation

Red blood cells

New polycythemia vera treatment approved in U.S.

Recent Oncology News

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

August 28, 2026

Takeda to Present New Data Highlighting Patient Centered Research in Hematologic, Thoracic and Gastrointestinal Cancers at the 2026 ASCO Annual Meeting

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 5, 2026

At Takeda, we aspire to cure cancer, with inspiration from patients and innovation from everywhere.

Better Health, Brighter Future

Our Medicines

We're committed to advancing treatment options that enhance & extend the lives of people living with cancer.

Oncology Pipeline

Our R&D efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers.

Patient Advocacy & Support

We're committed to helping people living with cancer navigate their journey – from diagnosis to survivorship.

Connect with Us

Contact Takeda Oncology for resources, information, or support.